Should You Buy Chewy Stock Before March 25?

Analysts forecast 2025 revenue +6% and adjusted EBITDA +25%; Chewy has an enterprise value of $8.9B and trades at roughly 9x next year's adjusted EBITDA. The business shows signs of stabilization—Autoship represented 83.9% of net sales in Q3 2025 (up from 79.2% in FY2024) and net-sales growth has settled into mid-single-digits—driven by Autoship, private-label expansion, marketplace ads, vet clinics and Chewy+. Key risks remain competition from Amazon, pandemic-era reversion and inflation-pressed discretionary spending; if Q4 metrics and expanding adjusted-EBITDA margins continue to improve, the stock may be materially undervalued despite a >70% decline over the past five years.

Analysis

Chewy’s current setup is less a pure e‑commerce growth story and more a consumer subscription + services play; that changes which competitive dynamics matter. The most important moat is recurring revenue and embedded distribution (autoship/subscriptions, health services, clinics, marketplace ads) — this raises customer LTV but also concentrates risk in “retention” levers (pricing, fulfillment, ad experience) rather than new customer acquisition efficiency.

Second‑order winners from a stabilizing Chewy are co‑packers and private‑label manufacturers who can scale volume without brand marketing, and ad tech providers that integrate retail data into targeting — they capture margin even as product margins compress. Conversely, independent vet clinics and upstream branded CPG players face squeezed pricing and margin mix pressure as Chewy expands vertically into services and white‑label lines; this can accelerate consolidation in pet supply manufacturing over 12–24 months.

Key catalysts and risks: the next earnings print can reprice implied growth expectations within days, but durable re‑rating requires multi‑quarter evidence of sustained retention, ad RPM expansion and health‑services monetization. Tail risks that would reverse the thesis include a renewed promotional price war from a scale competitor, a meaningful rise in customer churn, or a macro pullback in discretionary pet spending — any of which would show up first in LTV-to-CAC and gross margin trends over the coming quarters.

Contrarian edge: consensus treats Chewy as a beaten growth stock vulnerable to scale competition; what’s underpriced is optionality in adjacent high‑margin services (insurance, telehealth, clinics, targeted ads). If management executes on cross‑sell and retention, the multiple should re‑rate toward service‑led comp set valuations over 12–36 months — but execution is binary, so position sizing and protection matter.

Key Decisions for Investors

• Long CHWY equity (size 2–4% net exposure): accumulate on any >8% post‑earnings gap down with a 12‑month horizon. Target 40–60% upside if retention and service monetization steady; hard stop at 20% loss from entry or hedge with puts.
• Buy CHWY 6–9 month 25–30 delta puts as protection against earnings volatility while holding shares — cost should be treated as insurance (expect 3–6% net drag if used conservatively).
• Pair trade: Long CHWY (1x) / Short AMZN (0.2x) for 6–12 months to isolate pet ecosystem execution vs platform scale risk. Size short leg small (20% of notional long) to limit macro beta; target pair outperformance of CHWY by 30–50% if Chewy re‑monetizes services.
• Options asymmetry: if implied vol on CHWY spikes pre‑earnings, consider buying a cheap calendar (buy 3–6 month call, sell 1 month call) to monetize post‑print vol decay while keeping directional upside exposure. Close within 10 trading days post‑print to avoid assignment risk.